팝업레이어 알림

팝업레이어 알림이 없습니다.

Create health, happy lives and beautiful future

EDGC is at the center of the revolution beginning to disappear a border between industries as technologies converge.

  • Help to maintain healthy pregnancy by analyzing fetal chromosomal abnormalities.
  • Detect chromosomal abnormalities a baby may have.
  • Parents can take care of children’s health with proper treatment of analyzing their genes.
  • Analyze the genetic risk of diseases to help prevent them in advance.

Genetic Analysis Service Throughout the Life Cycle

  • What does
    your DNA look like?

    MIT Technology Review paid attention to
    ‘Genetic Fortune Telling’ in ’10 Breakthrough Technologies 2018’.
    Genes have all the information you may wish to know.
    Your genes exactly know your weaknesses, personality, aptitude and even the most effective exercises for you.
    Start to prepare for the era of the healthy 100-year life through genetic analysis.

  • EDGC is
    a global healthcare
    company.

    EDGC analyzes your genes based on
    cutting-edge genetic analysis technology and bioinformatics technology and suggests personalized lifestyle to help prevent diseases.

Business

EDGC Service

  • Non-Invasive Prenatal Test

    NICE®

    NICE® test, which has been verified its accuracy and reliability by acquiring CLIA and CAP certificates, detects fetal chromosomal abnormalities safely and easily.

  • Newborn Genetic Screening Test

    bebegene®

    bebegene® which detects chromosomal abnormalities such as major genetic diseases, Wilson’s Disease, ADHD, hearing loss and so on is the first test for a precious baby.

  • Integrated Genotype and Phenotype Test

    MYGENPLAN®

    MYGENPLAN® is the first integrated test in South Korea which analyzes metabolic genes and biological age and suggests personalized healthcare guide.

  • Cancer and General Disease Prediction Test

    gene2me® Plus

    gene2me® Plus predicts the genetic risk of major cancer, general diseases and eye diseases, and designs healthy future with early personalized treatment.

Recent News

EDGC Recent News

Article

Eone Diagnomics Genome Center's (EDGC) advanced cancer detecting technology using liquid biopsy has been approved by the government for good manufacturing practice (GMP) for clinical trials ― a giant step forward for the Incheon-based genetic sequencing and medical service company.The Ministry of Food and Drug Safety's approval on March 22, according to EDGC, has resolved a prerequisite condition for commercialization of "Onco-Catch," an in-vitro cancer-diagnosing service based on the technology which the company aims to introduce in the second half of 2022. "Onco" derives from oncology."Clinical trials are essential to commercialization of Onco-Catch, and getting the government's approval of GMP for clinical trials was a crucial step," an EDGC official told The Korea Times. He said the company will perform clinical trials on samples from cancer patients and non-patients who were authorized by medical facilities' institutional review boards.With the liquid biopsy technology, the company has been working on completing the predictive diagnosis of cancer by detecting signs of a circulating tumor DNA (ctDNA) ― a precursor to developing cancer. If there is any ctDNA, it exists in an extremely small amount amongst circulating free DNA (cfDNA) in blood.EDGC says its super-precision medical technology, once commercialized, can benefit people by enabling them to preemptively discover whether they will have cancer, find out if a cancer they had treated will relapse, and how effectively anti-cancerous treatments will progress in their bodies. EDGC says the precision medical industry is a "new paradigm" that will enable people to overcome diseases via prognosis, customized treatments and individualized health management instead of drugs and operations. The company, citing the Biotech Policy Research Center, said that the global precision medical industry is expected to expand its market to about 112 trillion won ($99 billion) by 2023."Once the industry gets mixed with the existing bio-health industries that involve medical, health and IT devices, the market pie will grow exponentially," the EDGC official said. In 2017, the global bio-health market was valued at about $1.73 trillion, according to the company.Along with America's GRAIL, EDGC is one of the leading companies in liquid biopsy based on next-generation genome sequencing. 

2021.03.24

Global Network

EONE-DIAGNOMICS GENOME CENTER

EDGC Promotion Video

No posts found.